GlassScriptPhysician profile
Nathan Boggs
NPI 1205393741
$6,454.63
in general payments reported to CMS, 2019-2025
28 companies · $834 in 2025
The $834 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $2,594 · 2023: $1,912 · 2024: $982 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Travel and Lodging: $747 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.55 |
| Travel and Lodging | $747.13 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,440.22 | 2022 | |
| Medtronic, INC. | $1,019.50 | 2023-2024 | Interstim |
| Janssen Biotech, INC. | $697.36 | 2022-2024 | Erleada |
| Sumitomo Pharma America, INC. | $520.70 | 2023-2025 | Gemtesa |
| Convatec INC. | $434.13 | 2022-2025 | |
| Endo USA, INC. | $347.39 | 2024-2025 | Xiaflex |
| Endo Pharmaceuticals INC. | $275.10 | 2021-2024 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $268.58 | 2022-2025 | Prolaris |
| Astellas Pharma US INC | $262.06 | 2021-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $219.22 | 2022-2025 | |
| Boston Scientific Corporation | $165.41 | 2022-2025 | Ams 700 |
| Procept Biorobotics Corporation | $154.12 | 2023 | Aquabeam Robotic System |
| Urogen Pharma, INC. | $95.17 | 2025 | |
| Urovant Sciences INC | $70.04 | 2022 | |
| Hollister Incorporated | $69.31 | 2022-2023 | Onli, Vapro Plus Pocket, Infyna Chic |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $67.19 | 2025 | Itind System |
| Abbvie INC. | $52.12 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $47.37 | 2025 | |
| Dendreon Pharmaceuticals LLC | $34.97 | 2025 | Provenge |
| Coloplast Corp | $30.86 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.95 | 2023 | Lifevest |
| 180 Medical, INC. | $28.03 | 2024 | Cure Twist |
| Laborie Medical Technologies Corp. | $27.37 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Telix Pharmaceuticals | $27.24 | 2024 | Illuccix |
| Antares Pharma, INC. | $25.18 | 2022 | |
| Rochester Medical Corporation | $21.42 | 2021 | |
| Halozyme INC | $13.68 | 2023 | |
| Alnylam Pharmaceuticals INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Boggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.